Atara shareholders approve reverse stock split (1:4–1:30) and 2024 Equity Incentive Plan

Atara Biotherapeutics, Inc.

Reverse stock split approved at board's discretion (ratio 1-for-4 to 1-for-30), board may abandon.
2024 Equity Incentive Plan approved: 53.96M for, 17.0M against, 24.84M broker non-votes.
Automatic annual increase to 2024 Equity Incentive Plan rejected: 26.63M for, 44.29M against.
Ratified Deloitte & Touche as auditors for FY2024: 89.69M for, 6.08M against.
Two directors elected: William K. Heiden and Ameet Mallik, each with >64M votes for.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.